U.S. Clinical Laboratory Services Market Size, Share & COVID-19 Impact Analysis, By Test Type (Clinical Chemistry, Hematology, Genetic Testing, Microbiology & Cytology, and Others), By Age (Pediatric and Adult), By Source of Payment (Public, Private, and Out of Pocket), and By Service Provider (Hospital-based Laboratories, Stand-alone Laboratories, Clinic-based Laboratories, and Others), and Country Forecast, 2023-2030

The U.S. clinical laboratory services market size was worth USD 102.68 billion in 2022 and is projected to grow at a CAGR of 7.0% during the forecast period. 

The U.S. has witnessed significant healthcare expenditure and growing demand for clinical laboratory tests for regular body check-ups and other long-term disorders. Similarly, the growing incidence of chronic and infectious diseases among the adult population is expected to increase the demand for clinical laboratory type of services. Also, the growing burden of diagnostic procedures contributes to clinical laboratory services in the U.S.

• According to Research Institute Foundation (2022), the undiagnosed diabetes population was around 8.5 million in the U.S. in 2021.  

Growing awareness regarding early diagnosis and reimbursement support by the public and private sectors is augmenting the clinical laboratory service adoption in the market. The COVID-19 pandemic positively impacted the market in 2020. This positive impact was due to the rising number of COVID-19 testing in the U.S. Also, major players experienced positive growth in their revenue due to increased patient visits during the pandemic.

LATEST TRENDS

Advancements in Lab Automation with an Aim to Provide Superior Services

The U.S. market is witnessing an increased focus and initiatives by prominent key players on developing automated clinical diagnostic labs and healthcare systems. Automation techniques and advanced machinery have become pervasive in clinical laboratory services.

In September 2022, Scitara Corporation announced a partnership with Agilent Technologies, Inc., to integrate its Scientific Integration Platform (SIP) with Agilent’s Software and Informatics Division portfolio of products, including chromatography software and lab workflow management solutions.

DRIVING FACTORS

Growing Prevalence of Chronic Disorders to Drive Market Growth

The mounting prevalence of chronic and infectious diseases, such as cystic fibrosis, sickle cell, Down Syndrome, and breast cancer, is projected to surge the demand for clinical laboratory services. Furthermore, the upsurge in the prevalence of chronic disorders has further led to an increasing number of hospitalizations and clinical laboratory tests prescribed by medical practitioners. For instance, according to an article published by National Center for Biotechnology Information (NCBI) in April 2023, 129,624 genetic tests were made available in the U.S., including updated versions of the previously existing ones.

Such substantial demand for early diagnosis, coupled with rising demand for clinical laboratory services, is contributing to the U.S. clinical laboratory services market growth.

RESTRAINING FACTORS

Request a Free sample to learn more about this report.

Pricing Pressure for Clinical Lab Tests Services to Hinder Market Expansion

The increasing demand for clinical laboratory tests might get hampered by several factors in the coming years. The increasing pricing pressure is one of the major factors, which is anticipated to hinder the market growth. The diagnostic industry is witnessing immense pricing pressure, mainly due to the diagnostic segment's deep discounting and unacceptable pricing practices.

For instance, in September 2022, in the U.S., 4 in 10 people deferred healthcare in the past year, with 28.0% delaying or canceling a medical procedure and 17.0% not filling a prescription due to the non-affordable pricing of tests in the region. Thus, the increasing pricing pressure for clinical laboratory services is anticipated to limit the market growth during the forecast period.

According to the Centers for Disease Control and Prevention, 2022, in the U.S., an estimated 28.7 million people (28.5% of the population) were diagnosed with diabetes, and around 8.5 million are undiagnosed.

SEGMENTATION

By Test Type Analysis

Based on test type, the market is segmented into clinical chemistry, hematology, genetic testing, microbiology & cytology, and others.

The clinical chemistry segment held the largest share in 2022 majorly due to the increasing prevalence of cardiovascular diseases, diabetes, and hormonal disorders across the U.S. Furthermore, the surge in the number of diagnostic labs in the country is expected to propel the market in the future.

• For instance, in an article published by the Centers for Disease Control and Prevention (CDC) in May 2023, Every year, about 805,000 people in the U.S. have a heart attack, and about 1 in 20 adults age 20 and older have coronary artery disease (CAD).

Such growing cases of chronic conditions in which clinical chemistry testing is necessary are expected to boost the U.S. market.

By Age Analysis

Based on age, the market is segmented into pediatric and adult.

The adult segment held a comparatively larger share in 2022. The growth of this segment is attributed to the rising number of adult patients visiting clinical laboratories, which is anticipated to drive the segment growth during the forecast timeframe. The adult or geriatric population is more prone to chronic and infectious diseases. Also, rising cardiac disorders and tuberculosis cases among adults are expected to drive the U.S. market.

• For instance, in March 2023, according to a report published by the Centers for Disease Control and Prevention (CDC) 2022, 8,300 tuberculosis-infected cases were reported in the U.S., compared with 7,874 cases reported in 2021.

By Source of Payment Analysis

Based on source of payment, the market is segmented into public, private, and out of pocket.

The public segment held a larger share in 2022, attributed to the increasing health insurance provided by government bodies and vital public players coupled with benefits such as high discounts, which are targeted mainly at low-income individuals or families.

• For instance, according to an article published by PETER G. PETERSON FOUNDATION in 2023, the U.S. government insurance programs, such as Medicare and Medicaid, encompass about 42.0% or USD 1.8 trillion of national healthcare spending.

By Service Provider Analysis

Based on service provider, the market is segmented into hospital-based laboratories, stand-alone laboratories, clinic-based laboratories, and others.

The hospital-based laboratories segment held a significant share in 2022. The growth of this segment is attributed to the rising number of collaborations between key market players and hospital laboratories to provide technologically advanced testing and services to patients. Additionally, the increasing number of patient admissions in hospitals across the U.S. is expected to drive segment growth in the future.

• For instance, according to an article published in 2021 by Sharps Compliance, Inc., hospital-based laboratories comprise about 5.0% and perform 55.0% of the volume test in the U.S.

KEY INDUSTRY PLAYERS

Regarding the competitive landscape, the market depicts the presence of established and emerging service companies. Laboratory Corporation of America, Quest Diagnostics Incorporated, and Eurofins Scientific dominated the U.S. clinical laboratory services market share in 2022. These companies' apex position is attributable to the robust service portfolio and a strong foothold in the U.S. market. In April 2020, Laboratory Corporation of America performed almost 35,000 to 40,000 daily tests.

Some of the other companies with a considerable presence in the U.S. market include Illumina, Inc., ARUP Laboratories, NeoGenomics Laboratories, Inc., and Sonic Healthcare Limited. The rising strategic initiatives are expected to enable companies to fortify their market presence.

LIST OF KEY COMPANIES PROFILED:

• Laboratory Corporation of America (U.S.)


• Quest Diagnostics Incorporated (U.S.)


• Illumina, Inc. (U.S.)


• Eurofins Scientific (Luxembourg)


• UNILABS (A.P. Moller Holding A/S) (Switzerland)


• NeoGenomics Laboratories, Inc. (U.S.)


• ARUP Laboratories (U.S.)


• Sonic Healthcare Limited (Australia)

KEY INDUSTRY DEVELOPMENTS: 

• March 2023- Illumina Inc. and Myriad Genetics Inc. expanded their strategic partnership to broaden the access and availability of oncology Homologous Recombination Deficiency (HRD) testing in the U.S.


• July 2022- Laboratory Corporation of America began testing for monkey pox using the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test. Labcorp is the first national laboratory to offer a Polymerase Chain Reaction (PCR) test, verified for the CDC, and the first to launch a more automated assay.


• May 2022- Laboratory Corporation of America announced the acquisition of diagnostic clinical laboratory services from AtlantiCare in Southern New Jersey to improve clinical lab services and help enhance patient care.

REPORT COVERAGE

An Infographic Representation of U.S. Clinical Laboratory Services Market

View Full Infographic

To get information on various segments, share your queries with us

The U.S. market research report provides a comprehensive market analysis. It focuses on key aspects such as the prevalence of key chronic diseases in the U.S. and industry development. Additionally, it includes the U.S. clinical laboratory services market trends and the impact of COVID-19 on the market. Further, the report also provides insights into the fundamental market dynamics and encompasses numerous factors that contributed to the market growth.

Report Scope & Segmentation